USA flag logo/image

An Official Website of the United States Government

Development of a nanosecond pulsed electric field system to treat skin cancer

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88848
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
CA123924
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOELECTROMED CORPORATION
849 MITTEN RD STE 104 BURLINGAME, CA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Development of a nanosecond pulsed electric field system to treat skin cancer
Agency: HHS
Contract: 1R43CA123924-01A2
Award Amount: $200,016.00
 

Abstract:

DESCRIPTION (provided by applicant): BioElectroMed is developing a new medical device called the NANOTOUCH that will utilize nanosecond pulsed electric fields to eliminate both benign and malignant skin lesions. We have used the NANOTOUCH to treat thre e different malignant lesions in mice, malignant melanoma, squamous cell carcinoma and basal cell carcinoma. With a total of 300 electric field pulses 300 ns in duration we are able to trigger both necrosis and apoptosis in all three of these tumor types. We have completed a long-term study in which a single melanoma was treated in each mouse. This pulsed field therapy exhibited 100% efficacy and resulted in complete regression within an average of 48 days in the 17 animals treated without recurrence for at least 150 days. Treating these malignant skin lesions with a total electric field exposure time of at most only 120 lts with the NANOTOUCH rapidly stimulates pyknosis within the tumor cells, reduces blood flow to the tumor and triggers both necrosis and a poptosis in murine melanoma tumors in vivo. This results in a mean tumor size regression of 90% within two weeks. Before we can obtain permission from the FDA to use the NANOTOUCH in human clinical trials, we must develop a new electrode design for use on much thicker human skin and then must demonstrate the efficacy of this new design on a mouse model. We will test four suction electrode configurations for compatibility with human skin and will then determine which of these is the most effective at elimina ting basal cell carcinomas in a mouse model that has most of the characteristics of human basal cell carcinoma. We will also develop a pulse delivery system that can be used in the clinical trials of the NANOTOUCH. If the NANOTOUCH can reliably eliminate b enign and malignant skin lesions, it would offer a welcome, scar-free alternative to surgery that could improve the quality of life for tens of thousands of dermatology patients. PUBLIC HEALTH RELEVANCE: We are developing a new medical device, the NANOTOUCH, for treating both benign and malignant skin lesions. The NANOTOUCH uses ultrashort electrical pulses to trigger skin tumors to self-destruct. It offers a scar-free alternative to surgery that could improve the quality of life for tens of tho usands of dermatology patients.

Principal Investigator:

Richard L. Nuccitelli
6503939507
RICH@BIOELECTROMED.COM

Business Contact:


rich@bioelectromed.com
Small Business Information at Submission:

BIOELECTROMED CORPORATION
BIOELECTROMED CORP 849 MITTEN RD STE 105 BURLINGAME, CA 94010

EIN/Tax ID: 943383868
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No